Imeka announced today that it will collaborate with GE Healthcare (NYSE:GE) to expand magnetic resonance imaging (MRI) for brain health.
Under the collaboration, GE Healthcare will integrate Imeka’s non-invasive neuroimaging technology into the BrainWave advanced diffusion processing package to allow researchers and clinicians to analyze diffusion MRI signals in the brain in greater detail.
GE Healthcare, in partnership with Medical Numerics, offers the BrainWave analysis and visualization tool for functional brain imaging data. According to a news release, the platform enables processing, analysis, 3D rendering and display of results from blood oxygen level-dependent (BOLD) MRI and diffusion tractography scans.
“GE Healthcare remains at the forefront of precision health – driven by our commitment to provide clinicians the tools and information they need to deliver the best patient care possible,” GE Healthcare GM of MR Applications Platform and Research Technologies Jason Polzin said in the release. “We are proud to collaborate with Imeka to offer medical practitioners advanced neuroimaging tools that make it easier, faster, and more efficient to make informed decisions and deliver personalized care for patients impacted by brain diseases.”
By combining BrainWave with Imeka’s neuroimaging processing technology, researchers and clinicians will be able to quickly obtain highly localized views of white matter, offering insights into the impact of central nervous system (CNS) diseases and disorders.
“Imeka has experienced rapid momentum over the past several months, including customer and company growth and collaborations with industry innovators like GE Healthcare,” Imeka CEO Jean-René Bélanger said. “Our Advanced Neuro Imaging Endpoints (ANIE) biomarker platform is helping scientists, researchers, and clinicians across pharma, life sciences, and healthcare organizations accelerate the search for and development of cures for brain diseases.
“We are excited to partner with GE Healthcare, a pioneer in medical imaging, to expand into additional markets and help clinicians improve patient outcomes.”